We are pleased to announce that AmeriHealth will coordinate with our
Pharmacy Services department to facilitate Synagis®
(palivizumab) for the 2011-2012 respiratory syncytial virus (RSV) season, which
is November through April in the United States. RSV is the most common cause of
bronchiolitis and pneumonia among children younger than one year of age. During
the RSV season, we will approve the monthly administration of
Synagis® (palivizumab) for at-risk children younger than two
years of age.
It is mandatory for all participating providers to obtain
Synagis® (palivizumab) through ACRO Pharmaceutical Services.
AmeriHealth will coordinate with ACRO Pharmaceutical Services to facilitate
delivery of Synagis® (palivizumab) to your office.
If you have questions about the Synagis®(palivizumab)
distribution program, please contact Customer Service at 1-800-275-2583.
Look for more information regarding the shipment and facilitation of
Synagis® (palivizumab) in next month's edition of Partners in
Health Update.
Note: MedImmune, LLC, the makers of Synagis®
(palivizumab), has a voluntary program called RSV Connection™.
However, AmeriHealth does not participate in this program. All requests for
Synagis® (palivizumab) should be sent directly to ACRO
Pharmaceutical Services.